Bcl-2 expression and response to chemotherapy in colorectal adenocarcinomas

British Journal of Cancer

Volumn 75, Issue 3, 1997, Pages 427-431

  Schneider, H J ^a,c   Sampson, S A ^a   Cunningham, D ^a   Norman, A R ^a   Andreyev, H J N ^a,b   Tilsed, J V T ^a   Clarke, P A ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c QUEEN MARY S HOSPITAL   (United Kingdom)

Author keywords

5 fluorouracil; bcl 2; Chemotherapy; Colorectal cancer

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; PROTEIN BCL 2;

ADENOCARCINOMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; COLORECTAL CARCINOMA; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION;

EID: 0031032481     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.70     Document Type: Article

References (43)

1. Akao Y, Otsuki Y, Kataoka S, Ito Y, and Tsujimoto Y (1994) Multiple subcellular localisation of bcl-2: deletion in nuclear outer memebrane, endoplasmic reticulum membrane and mitochondrial membranes. Cancer Res 54: 2468-2471
2. Bakhshi A, Jenson JP, Goldman P, Wright JJ, Mcbride OW, Epstein AL and Korsmeyer SJ (1985) Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 41: 899-906
3. Baretton GB, Diebold J, Christoforis G, Vogt M, Muller C, Dopfer K, Schneiderbanger K, Schmidt M and Lohrs U (1996) Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Cancer 77: 255-264
4. Ben Ezra JM, Kornstein MJ, Grimes MM and Krystal G (1994) Small cell carcinomas of the lung express the Bcl-2 protein. Am J Pathol 145: 1036-1040
5. Bhargava V, Kell DV, Van De Rijn M and Warnke RA (1994) Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol 145: 535-540
6. Boise LH, Gottschalk AR, Quintans J and Thompson CB (1995) Bcl-2 and Bcl-2-related proteins in apoptosis regulation. Curr Top Microbiol Immunol, 200: 107-121
7. Bosari S, Moneghini L, Graziani D, Lee AKC, Murray JJ, Coggi G and Viale G (1995) Bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas. Hum Pathol 26: 534-540
8. Caltoretti G, Pileri S, Parravicini C, Becker MHG, Poggi S, Bifulco C, Key G, D'Amaio L, Sabattini E, Feudale E, Reynolds F, Gerdes J and Rilke F (1993) Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections. J Pathol 171: 83-98
9. Chung CK, Zaino RJ and Stryker JA (1982) Colorectal carcinoma: evaluation of histologic grade and factors influencing prognosis. J Surg Oncol 21: 143-148
10. Chiou SK, Rao L and White E (1994) Bcl-2 blocks p53-dependent apoptosis. Mol Cell Biol 14: 2556-2563
11. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S and Buttyan R (1993) Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143: 390-400
12. Cunningham D and Findlay M (1993) The chemotherapy of colon cancer can no longer be ignored. Eur J Cancer 29: 2077-2079
13. Fisher TC, Milner AE, Gregory CD, Jackman AL, Aherne GW, Hartley JA, Dive C and Hickman JA (1993) Bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res 53: 3321-3327
14. Gee JM, Robertson JF, Ellis IO, Wilsher P, Mcclelland RA, Hoyle HB, Kyme SR, Finlay P, Blamey RW and Nicholson RI (1994) Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 59: 619-628
15. Hague A, Moorghen M, Hicks D, Chapman M and Paraskeva C (1994) BCL-2 expression in human colorectal adenomas and carcinomas. Oncogene 9: 3367-3370
16. Hellemans P, Van Dam PA, Weyler J, Van Oosterom AT, Buytarrt P and Van Marck E (1995) Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer 72: 354-360
17. Hermine O, Haioun C, D'Agay M-F, Briere J, Lavignac C, Fillet G, Salles G, Marolleau J-P, Diebold J, Reyes F and Gaulard P (1996) Prognostic significance of bcl-2 protein expression in aggressive non-hodgkin's lymphoma. Blood 87: 265-272
18. Hill M, Norman A, Cunningham D, Findlay M, Nicolson V, Hill A, Iveson A, Evans C, Joffe J, Nicolson M and Hickish T (1995a). Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol 13: 1297-1302
19. Hill M, Norman A, Cunningham D, Findlay M, Watson M, Nicolson V, Webb A, Middleton G, Ahmed F, Hickish T, Nicolson M, O'Brien M, Iveson T, Iveson A and Evans C (1995b). Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. J Clin Oncol 13: 2317-2323
20. Hill ME, Maclennan K, Cunningham D, Vaughan Hudson B, Burke M, Clarke PA, Di Stefano F, Andersen L, Vaughan-Hudson G, Mason D and Linch DC (1996) Prognostic significance of bcl-2 expression and bcl-2 MBR rearrangement in diffuse large cell non-Hodgkin's lymphoma: A BNLI study. Blood 88: 1046-1051
21. Hockenberry D, Zutter M, Hickey W, Nahm M and Korsmeyer SJ (1991) BCL2 protein is topographically restricted in tissues characterized by apoplotic cell death. Proc Natl Acad Sci 88: 6961-6965
22. Hurlimann J, Larringa B and Vala DL (1995) Bcl-2 protein in invasive ductal breast carcinomas. Virchows Arch 426: 163-168
23. Ijiri K and Potten CS (1983) Response of intestinal cells of differing topographical and hierarchical status to ten cytotoxic drugs and five sources of radiation. Br J Cancer 47: 175-185
24. Joensuu H, Pylkkanen L and Tiokkanen S (1994) Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 145: 1191-1198
25. Johnsion PG, Lenz H-J, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV and Leichman L (1995) Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55: 1407-1412
26. Korsmeyer SJ (1992) Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blond 80: 879-886
27. Kuwashima Y, Uehara T, Kishi K, Shiromizu K, Matsuzawa M and Takayama S (1994) Immunohistochemical characterization of undifferentiated carcinomas of the ovary. J Cancer Res Clin Oncol 120: 672-677
28. Lauwers GY, Scott GV and Karpeh MS (1995) Immunohistochemical evaluation of bcl-2 protein expression in gastric adenocarcinomas. Cancer 75: 2209-2213
29. Leek RD, Kaklamanis L, Pezzella F, Gatter KC and Harris AL (1995) Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 69: 135-139
30. McDonnell TJ, Tronosco P, Brisbay SM, Logothetis C, Chung LW, Hseich JT, TU SM and Campbell ML (1992) Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940-6944
31. Miyashita T and Reed J (1992) Bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 52: 5407-5411
32. Moertel CG (1994) Chemotherapy for colorectal cancer N Engl J Med 330: 1136-1143
33. Ofner D, Riehmann K, Maier H, Riedmann B, Nehoda H, Totsch M, Bocker W, Jasani B and Schmid KW (1995) Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br J Cancer 72: 981-985
34. Oltvai ZN, Milliman CL and Korsmeyer SJ (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619
35. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnhill MS, Pierce CB, Harris A, Gatter KC and Mason DY (1993) Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 329: 690-694
36. Sierra A, Lloveras B, Castellsague X, Moreno L, Garcia-Ramirez M and Fabra A (1995) Bcl-2 expression is associated with lymph node metastasis in human ductal breast carcinoma. Int J Cancer 60: 54-60
37. Sinicrope FA, Hart J, Michelassi F and Lee JJ (1995a). Prognostic value of bcl-2 oncogene expression in stage II colon carcinoma. Clin Cancer Res 1: 1103-1110
38. Sinicrope FA, Ruan S, Cleary KR, Lee JJ and Levin B (1995b) Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 55: 237-241
39. Theodorakis P, D'Sa-Eipper C, Subramanian T and Chinnadurai G (1996) Unmasking of a proliferation-restraining activity of the anti-apoptosis protein EBV BHRF1. Oncogene 12: 1707-1713
40. Vaux DL, Cory S and Adams JM (1988) Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335: 440-442
41. Wallon MI, Whysong D, O'Conner PM, Hockenberry D, Korsmeyer SJ and Kohn KW (1993) Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res 53: 1853-1861
42. Watson AJM, Merritt AJ, Jones LS, Askew JN, Anderson E, Beddiolini A, Balzi M, Potten CS and Hickman JA (1996) Evidence for reciprocity of bcl-2 and p53 expression in human colorectal adenomas and carcinomas. Br J Cancer 73: 889-895
43. Webb A, Scott-Mackie P, Cunningham D, Norman A, Andreyev J, O'Brien M and Benstead J (1995) The prognostic value of CEA, beta HCG, AFP, CA 125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer. Ann Oncol 6: 581-587